2 Information about icosapent ethyl
Marketing authorisation indication
2.1 Icosapent ethyl (Vazkepa, Amarin Corporation) is indicated 'to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [1.7mmol/l]) and:
-
established cardiovascular disease, or
-
diabetes, and at least on other cardiovascular risk factor'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for icosapent ethyl.